Profile data is unavailable for this security.
About the company
Embla Medical hf, formerly Ossur hf, is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company's business activities are divided into three business segment: The Prosthetics, its product portfolio includes a range of lower and upper limb prosthetic components; The Bracing & Supports, which offers the Unloader One range of knee braces that relieve pain from knee osteoarthritis, as well as the Unloader Hip which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip; and The Patient Care, which operates a network of Patient Care clinics around the world, with each one catering to individual patients and their needs.
- Revenue in DKK (TTM)5.85bn
- Net income in DKK480.44m
- Incorporated1971
- Employees4.00k
- LocationEmbla Medical hfGrjothals 5REYKJAVIK 110IcelandISL
- Phone+354 5151300
- Fax+354 5151366
- Websitehttps://www.emblamedical.com/
More ▼
Mergers & acquisitions
| Acquired company | EMBLA:CPH since announced | Transaction value |
|---|---|---|
| FIOR & GENTZ Gesellschaft fuer Entwicklung und Vertrieb von orthopaedietechnischen Systemen mbH | 27.82% | 131.38m |
Data delayed at least 15 minutes, as of Nov 11 2024 14:22 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RaySearch Laboratories AB (publ) | 725.75m | 97.24m | 3.34bn | 403.00 | 44.23 | 8.70 | 12.37 | 4.60 | 4.41 | 4.41 | 32.91 | 22.41 | 0.5701 | 4.50 | 3.11 | 2,901,244.00 | 7.64 | 1.29 | 11.80 | 1.88 | 90.48 | 90.57 | 13.40 | 2.55 | 1.17 | -- | 0.3937 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| CellaVision AB | 474.04m | 96.60m | 3.73bn | 228.00 | 38.59 | 7.55 | 30.21 | 7.86 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| Surgical Science Sweden AB | 539.04m | 127.15m | 3.97bn | 265.00 | 31.26 | 1.35 | 24.20 | 7.37 | 3.87 | 3.87 | 16.43 | 90.02 | 0.1695 | 1.49 | 7.35 | 3,224,027.00 | 4.00 | 4.49 | 4.26 | 4.78 | 68.51 | 70.06 | 23.59 | 23.75 | 3.46 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Arjo AB (publ) | 7.19bn | 328.60m | 5.80bn | 6.85k | 18.92 | 1.23 | 6.03 | 0.8069 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Revenio Group Oyj | 761.16m | 141.75m | 5.82bn | 230.00 | 40.62 | 7.69 | 32.19 | 7.65 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Biotage AB | 1.37bn | 165.27m | 8.38bn | 675.00 | 50.72 | 3.42 | 29.75 | 6.13 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| ChemoMetec A/S | 407.87m | 136.28m | 8.43bn | 173.00 | 61.85 | 14.91 | 54.74 | 20.67 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Xvivo Perfusion AB | 482.68m | 131.36m | 9.13bn | 161.00 | 68.47 | 6.81 | 51.42 | 18.91 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 6.44bn | 75.24m | 10.51bn | 2.36k | 144.47 | 3.30 | 15.58 | 1.63 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Embla Medical hf | 5.85bn | 480.44m | 15.34bn | 4.00k | 32.14 | 2.81 | 17.85 | 2.62 | 1.12 | 1.12 | 13.55 | 12.76 | 0.5755 | 2.23 | 6.65 | 1,461,696.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 11.65bn | 728.59m | 15.43bn | 4.57k | 21.97 | 2.32 | 10.39 | 1.32 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Vitrolife AB | 2.29bn | -2.45bn | 20.90bn | 1.10k | -- | 2.47 | -- | 9.15 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Ambu A/S | 5.39bn | 235.00m | 29.10bn | 5.20k | 140.11 | 5.90 | 31.26 | 5.40 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
Data as of Nov 11 2024. Currency figures normalised to Embla Medical hf's reporting currency: Danish Krone DKK
8.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SEB Investment Management ABas of 30 Sep 2024 | 17.58m | 4.11% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 5.68m | 1.33% |
| ODIN Forvaltning ASas of 31 Oct 2024 | 4.98m | 1.16% |
| Artisan Partners LPas of 30 Sep 2024 | 4.14m | 0.97% |
| Fondita Fund Management Co. Ltd.as of 30 Sep 2024 | 1.33m | 0.31% |
| Apo Asset Management GmbHas of 28 Mar 2024 | 1.00m | 0.23% |
| Bessemer Investment Management LLCas of 31 Jul 2024 | 913.88k | 0.21% |
| Lazard Fr�res Gestion SASas of 28 Mar 2024 | 763.89k | 0.18% |
| Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2024 | 685.00k | 0.16% |
| Danske Bank A/S (Investment Management)as of 31 Aug 2024 | 676.27k | 0.16% |
More ▼
Data from 30 Apr 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
